)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Clearside Biomedical
Clearside Biomedical (CLSDQ) investor relations material
Clearside Biomedical has been otc
Clearside Biomedical Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Focused on suprachoroidal space (SCS) drug delivery, with XIPERE as the first FDA-approved product for uveitic macular edema.
In July 2025, initiated a strategic review, including potential sale, licensing, or other transactions, and transitioned all employees to consulting roles.
Paused all internal R&D programs to conserve cash while seeking strategic alternatives.
Financial highlights
Net loss of $5.97 million for Q3 2025, improved from $7.69 million in Q3 2024; net loss of $18.69 million for the nine months ended September 30, 2025, versus $27.05 million in the prior year period.
License and other revenue was $0.2 million for Q3 2025, down from $1.0 million in Q3 2024; $3.0 million for the nine months, up from $1.4 million in 2024.
Cash and cash equivalents were $6.8 million as of September 30, 2025, down from $20.0 million at year-end 2024.
Operating cash outflow was $16.0 million for the nine months ended September 30, 2025.
Outlook and guidance
Current cash is insufficient to fund operations for the next 12 months; substantial doubt exists about the ability to continue as a going concern.
Exploring strategic alternatives; if unsuccessful, may need to file for bankruptcy or wind down operations.
All internal R&D paused; future activities depend on additional capital or successful strategic transaction.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Clearside Biomedical
- CLS-AX advances toward phase III with flexible dosing, strong safety, and active partnership outreach.CLSDQ
Stifel 2025 Virtual Ophthalmology Forum - Key votes include director elections, say-on-pay, auditor ratification, and doubling authorized shares.CLSDQProxy Filing
- Proxy covers director elections, say-on-pay, auditor ratification, and doubling authorized shares.CLSDQProxy Filing
- Vote sought on reverse stock split and share reduction to maintain Nasdaq listing.CLSDQProxy Filing
- CLS-AX maintained vision, reduced injections by 84%, and showed strong safety in wet AMD.CLSDQStudy Result
- Flexible, safe suprachoroidal dosing in wet AMD sets up broad phase III launch in 2025.CLSDQStifel 2024 Healthcare Conference
- CLS-AX met Phase 2b endpoints; Q3 net loss narrowed, funding secured into Q3 2025.CLSDQQ3 2024
- Suprachoroidal delivery platform advances with strong clinical data, safety, and late Q3 2024 data expected.CLSDQStatus Update
- CLS-AX advances to phase 3, leveraging flexible dosing and suprachoroidal delivery for wet AMD.CLSDQOppenheimer 35th Annual Healthcare Life Sciences Conference 2025
- FDA-aligned phase III CLS-AX trials advance as cash supports operations into late 2025.CLSDQQ4 2024
Clearside Biomedical
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Clearside Biomedical, Inc. is a biopharmaceutical company specializing in the development of therapies for the treatment of eye diseases. The company focuses on treating conditions affecting the retina and choroid through its proprietary SCS Microinjector platform, which delivers drugs directly to the back of the eye. Clearside's approach aims to enhance the efficacy of treatments for serious vision-threatening diseases, including macular edema and uveitis. The company is headquartered in Alpharetta, United States, and its shares are listed on the NASDAQ.